 |
|
A Systematic Review of Alternative Therapies in the Irritable Bowel Syndrome
Jennifer A. Spanier, BS;
Colin W. Howden, MD;
Michael P. Jones, MD
Arch Intern Med. 2003;163:265-274.
ABSTRACT
The irritable bowel syndrome is a common disorder associated with a significant burden of illness, poor quality of life, high rates of absenteeism, and high health care utilization. Management can be difficult and treatment unrewarding; these facts have led physicians and patients toward alternative therapies. We explored a variety of treatments that exist beyond the scope of commonly used therapies for irritable bowel syndrome. Guarded optimism exists for traditional Chinese medicine and psychological therapies, but further well-designed trials are needed. Oral cromolyn sodium may be useful in chronic unexplained diarrhea and appears as effective as and safer than elimination diets. The roles of lactose and fructose intolerance remain poorly understood. Alterations of enteric flora may play a role in irritable bowel syndrome, but supporting evidence for bacterial overgrowth or probiotic therapy is lacking.
INTRODUCTION
The irritable bowel syndrome (IBS) is a common disorder, with a prevalence of 14% to 24% in women and 5% to 19% in men.1 Although most individuals meeting diagnostic criteria for IBS will not seek care, it accounts for 12% of visits to primary care physicians and 28% of visits to gastroenterologists.2-3 In addition, IBS is associated with significant impairment in quality of life, high rates of absenteeism, and significantly increased health care costs.4-7
Effective therapies are lacking. More than a decade ago, Klein8 commented that "not a single study has been published that provides compelling evidence that any therapeutic agent is efficacious in the global treatment of IBS." Little has changed. Attempts to introduce agents acting via serotonergic receptors have met with concerns about safety and efficacy.9-10 In addition, managed-care pressures have limited the time physicians can spend with patients. This is highly detrimental, as the physician-patient relationship is a critical determinant of treatment success.
The lack of efficacious therapies and diminution of the physician-patient relationship have been accompanied by increased use of complementary and alternative therapies.11 Between 11% and 43% of patients with gastrointestinal disorders use alternative or complementary techniques, and many consider them beneficial.12-13 Unfortunately, physicians are generally not well acquainted with these therapies, and there is a scarcity of reasonable data with which to become acquainted. This article reviews the available literature for alternative or complementary treatments of IBS.
METHODS
DATA SOURCES
All published English-language studies were identified by a comprehensive search of the MEDLINE database from 1966 through 2001. Bibliographies of index references meeting inclusion criteria were searched for additional references.
INCLUSION AND EXCLUSION CRITERIA
Study selection criteria were defined a priori. Candidate studies included clinical trials performed in adults with IBS. Evaluable therapies included acidophilus, acupuncture, allergy, aloe, alternative medicine, bacterial overgrowth, biofeedback hypnotherapy, chemical sensitivity, Chinese medicine, colonic irrigation, diet, Lactobacillus, peppermint oil, and probiotics. Unevaluable therapies included aromatherapy, Candida, enemas, ginger, herbs, massage, meditation, reflexology, supplements, and vitamins.
Only studies published in full were evaluated. Abstracts, letters, incomplete reports in book chapters, and reviews were excluded. Nonrandomized or uncontrolled studies were excluded.
DATA EXTRACTION
Trial outcomes and methods were evaluated independently by 2 investigators (J.A.S. and M.P.J.). A third investigator (C.W.H.) resolved discrepancies. Symptom improvement was defined as a 50% or greater decrease in total symptom scores. In studies using different symptom-reporting scales, the relative percentage change in global symptoms was determined. All studies were analyzed by means of an intention-to-treat analysis. Methodologic quality of each trial was assessed by means of the following standard scoring system to measure the likelihood of bias14:
Give 1 point for each "yes" and 0 point for each "no":
- Was the study described as randomized?
- Was the study described as double-blind?
- Was there a description of withdrawals and dropouts?
- Was the method to generate the sequence of randomization described and was it appropriate?
- Was the method of double-blinding described and was it appropriate?
Deduct 1 point if:
- The method to generate the sequence of randomization was described and it was inappropriate
- The method of double-blinding was described and it was inappropriate
DATA ANALYSIS
Statistical combination of trial results was performed with RevMan 4.1 meta-analysis software issued by the Cochrane Collaboration, Oxford, England. The measure of association was the odds ratio, which, along with 95% confidence intervals and tests for heterogeneity, was calculated by means of a fixed-effects model. Differences between treatment and placebo groups and differences between placebo groups were assessed by  2 analysis.
RESULTS
HERBAL REMEDIES
Patients commonly use dietary supplements and herbal remedies, yet few supporting data exist. Only one randomized, double-blind, placebo-controlled trial of traditional Chinese medicine has been published in English.15 In this study, 106 patients with IBS by Rome criteria were randomized to individualized herbal preparations, standardized herbal preparations, or placebo. After 16 weeks, digestive symptoms were significantly improved over those with placebo treatment in both treatment groups. Individualized preparations were no different from the standardized formulation at 16 weeks, but did show greater sustained improvement after an additional 14 weeks of follow-up.
An Ayurvedic preparation containing Aegle marmelos correa and Bacopa monniere was compared with standard medical therapy or placebo in a 6-week, double-blind, randomized, controlled trial.16 The rate of improvement was 65% for Ayurvedic therapy, 78% for standard therapy, and 33% for placebo. Ayurvedic therapy was noted to be particularly helpful in patients with diarrhea. Relapse rates at 6 months were similar in all groups.
COMMERCIALLY AVAILABLE SUPPLEMENTS AND PREPARATIONS
A variety of commercial products are marketed to treat IBS. The most widely used agents are peppermint oil, ginger, and aloe. In addition, a number of plant extracts are used to treat constipation, and these were recently reviewed elsewhere.17
Ginger
No studies have specifically evaluated ginger in the management of IBS. Ginger has been used to treat nausea. Several methodologically sound studies have assessed the efficacy of ginger in the treatment of postoperative nausea and vomiting.18-21 Pooled analyses of these data are shown in Figure 1. No difference exists between ginger and placebo in preventing postoperative nausea and vomiting. A similar conclusion was reached by Ernst and Pittler22 in a recent systematic review of the subject. Two additional controlled studies have shown benefit for ginger in preventing seasickness and reducing symptoms in hyperemesis gravidarum.23-24
|
|
|
|
Figure 1. Ginger capsules vs placebo in the control of postoperative nausea and vomiting. OR indicates odds ratio; CI, confidence interval.
|
|
|
Aloe
Aloe is commonly used in IBS, particularly the constipation-predominant subtype. Although aloe is commonly considered a safe, "natural" remedy, the active ingredients are anthraquinones. No data presently exist regarding the use of aloe in IBS. Odes and Madar25 showed that a preparation containing celandin, aloe vera, and psyllium resulted in greater symptom reduction than placebo in a group of 35 patients with chronic constipation. The preparation was not helpful in reducing abdominal pain scores.
Peppermint Oil
Peppermint oil has antispasmodic properties. The principal active ingredient of peppermint oil is menthol, which is a cyclic monoterpene that relaxes smooth muscle by blocking calcium influx.26 Because of this, peppermint oil is frequently used to treat IBS as well as dyspepsia. Although a number of studies have been performed, efficacy remains unclear.
Seven randomized controlled trials were identified and 2 were excluded. One study was performed in a predominantly male population of Taiwanese veterans with IBS.27 Peppermint oil was superior to placebo in improving symptoms after 1 month of therapy. The study was excluded, as the population was not representative of the patient population seen by most clinicians. A second study was excluded because it was performed in children.28 This study also found peppermint oil superior to placebo after 2 weeks of therapy.
The remaining 5 trials are summarized in Table 1. Four of the 5 trials were sufficiently comparable in method to attempt meta-anlysis.29-32 The result of this analysis modestly favored peppermint oil over placebo (odds ratio, 2.70; 95% confidence interval, 1.56-4.76). This is consistent with a similar analysis performed by Pittler and Ernst.35 However, our analysis showed significant heterogeneity, which limits interpretability (2 = 20.81; P<.001). Pittler and Ernst did not assess heterogeneity, as they used a random-effects rather than fixed-effects model. In addition, the duration of treatment in all studies never exceeded 3 weeks.
|
|
|
|
Table 1. Double-blind, Placebo-Controlled, Crossover Trials of Peppermint Oil in Irritable Bowel Syndrome
|
|
|
The study by Lawson et al33 was not included in the meta-analysis because of methodologic differences. This trial of 25 subjects studied for 4 weeks did not find peppermint oil superior to placebo.
ALTERATION OF INTESTINAL MICROFLORA
Our understanding of the complex relationship between host and enteric microflora is evolving but crude. Recent investigations have highlighted the development of IBS after bacterial gastroenteritis.36-38 Mechanistic observations in this area are scant and disparate. Postenteritic IBS has been suggested to be due to persistent alterations in gut neuroendocrine function and permeability39 as well as psychosocial predisposition toward symptom embracement.40-41
Bacterial Overgrowth
Flatulence, bloating, and altered stool consistency can be seen in both IBS and bacterial overgrowth, and a recent uncontrolled, retrospective analysis reported that much of IBS was attributable to small-intestinal bacterial overgrowth.42 This study has been widely embraced by the lay press and widely criticized by the scientific community.43-46 Prospective controlled investigations are needed in this area before conclusions can be drawn.
Probiotics
Although unproven, probiotics are commonly used in the form of yogurt or acidophilus cultures. The probiotic Lactobacillus plantarum was administered in a randomized, placebo-controlled, double-blind fashion for 4 weeks to patients meeting Rome criteria for IBS.47 Treated patients had significant reductions in flatulence and abdominal pain and improved defecatory satisfaction at 6 and 52 weeks. However, a second randomized, double-blind, placebo-controlled trial of 19 patients with Rome criteria–defined IBS failed to show benefit after treatment with Lactobacillus GG.48 A trend toward improvement was noted, however, for a reduction in the number of unformed bowel motions in treated patients with diarrhea. Oligofructose and inulin are probiotic agents reported to increase bifidobacteria in feces and increase stool weight, which makes them attractive in the management of constipation.49 A randomized, controlled, double-blind crossover study of the probiotic oligofructose in 21 patients with IBS, however, failed to detect any effects on symptoms, whole-gut transit time, fecal weight, or pH.50
DIETARY MODIFICATION, FOOD ALLERGY, AND INTOLERANCE
Exclusion Diets
Dietary modification is a cornerstone of IBS management. Adverse reactions to food are common, particularly in diarrhea-predominant forms. Positive responses to elimination diets range from 15% to 71%, with double-blind, placebo-controlled challenges identifying problem foods in 6% to 58% of cases.51-52 Milk, wheat, and eggs are most frequently identified.
The generic implementation of exclusion diets was evaluated by King et al53 in a crossover controlled trial of healthy control subjects and patients with IBS meeting Rome criteria. Compared with controls, patients with IBS produced similar total volumes of colonic gas but significantly more hydrogen. An exclusion diet eliminating beef, wheat, and dairy products significantly reduced total and hydrogen gas production by both groups and abolished differences between IBS and control subjects with respect to hydrogen gas production. This was accompanied by a significant reduction in total symptom score.
Cromolyn Sodium
Two studies have compared oral cromolyn with placebo in randomized, double-blind crossover trials; one study evaluated diarrhea-predominant IBS,54 while the second study included patients with chronic unexplained diarrhea.55 Bolin55 found that none of 20 patients responded to placebo, whereas 6 of 20 patients had greater than 50% decrease in stool frequency with a 4-week course of oral cromolyn. Lunardi et al54 noted that 8-week treatment with oral cromolyn resulted in significantly greater symptom reduction than placebo, and a long carryover effect was seen in the group initially treated with cromolyn.
Two uncontrolled, unblinded studies have compared oral cromolyn with elimination diet. The largest involved 409 patients with well-defined IBS who were examined over 4 months.56 Symptom improvement was noted in 60% of patients treated with elimination diet and 67% of cromolyn-treated patients. Response rates in both groups were better for patients with positive skin tests for dietary antigens. The same investigators reported a similar 60% response to cromolyn in a group of 101 patients with diarrhea-predominant IBS who had previously improved with elimination diet.57
DIGESTIVE SUPPLEMENTS
Bulking Agents
Dietary supplements are commonly used to treat IBS, and the most widely prescribed of these are bulking agents. Bulking agents were recently reviewed by Jailwala and colleagues.58 Of 13 trials, 4 demonstrated efficacy and 3 of 4 positive trials were considered methodologically of high quality. Most studies reported improvement in nonspecific outcomes. Less benefit was seen for specific symptoms such as stool frequency, pain, and bloating. The authors concluded that the efficacy of bulking agents was not clearly established. A similar review concluded that bulking agents appear to have efficacy in the treatment of constipation, but little efficacy for the entire IBS symptom complex.59
Pancreatic Enzymes
Many patients with IBS use digestive enzyme supplements such as papaya extract, lactase, ox bile extract, and pancreatic enzymes or pancreatic extracts. The utility of any of these is unproven. A single trial of pancreatic enzymes given with a large fatty meal reported significant reductions in postprandial bloating in healthy subjects.60 Unfortunately, the assessment period was just the day of the test meal and subjects were at most mildly symptomatic, with mean scores for bloating of 0.2 and 0.6 cm on a 6-cm visual analog scale. Bloating was the only symptom that improved; no significant changes were seen for gas, pain, nausea, or fullness.
Lactose and Fructose Intolerance
Carbohydrate intolerance receives a great deal of attention in IBS. Lactase nonpersistence is common in much of the world, but its prevalence varies across populations. For example, a study of Italian patients with unexplained abdominal pain and intermittent diarrhea reported lactose intolerance in 74% compared with a population prevalence of 34%.61 A study in non-Jewish whites of northern-western European ancestry found lactase deficiency in only 6% of both subjects with IBS and healthy control subjects.62 A study of British subjects found lactase deficiency in 4.7% of asymptomatic whites and 75% of asymptomatic nonwhites.63 Lactase deficiency was identified in 16 (8%) of 200 patients with IBS and was not different from baseline population prevalence. Vesa and colleagues64 identified 101 lactose maldigesters among 427 healthy subjects. Subjects were further characterized as meeting Rome criteria for IBS. Diagnostic symptoms for IBS were present in 15% of both lactose digesters and maldigesters. Among subjects who considered themselves dairy intolerant, equal proportions were lactose digesters and maldigesters.
Fructose malabsorption has also been evaluated in IBS. Fructose malabsorption (identified by breath testing) was reported in 13 of 25 Danish patients with IBS, with subjects being both clinically and biochemically positive.65 There was no control group. Fructose-sorbitol malabsorption was seen in 30% of patients with IBS and 40% of control subjects.66 Thirty-one (44%) of the patients with IBS developed symptoms during testing, compared with 3 (4%) of 85 controls. Symptomatic and asymptomatic subjects did not differ with regard to the presence or absence of fructose-sorbitol malabsorption. A prospective evaluation compared lactose, fructose, sorbitol, and sucrose absorption in 25 consecutive outpatients with IBS and 12 healthy control subjects.67 Malabsorption of at least 1 test sugar was present in more than 90% of all subjects. Although rates of carbohydrate malabsorption were similar, patients with IBS reported more symptoms after sugar ingestion than control subjects did. These data suggest that carbohydrate malabsorption may not be more prevalent in those with IBS or self-reported dairy intolerance, but these patients develop a greater degree of symptoms or are more bothered by their symptoms.
Four open, uncontrolled studies have evaluated response to a lactose-restricted diet. Fernandez-Banares et al67 reported that 40% of patients with IBS with intolerance to lactose, fructose, sorbitol, or sucrose clinically improved after intake of the offending sugar was restricted. A similar study in Israeli patients with IBS symptoms identified lactose malabsorption in 82%, fructose malabsorption in 43%, and fructose-sorbitol malabsorption in 70%.68 Symptom assessment after 1-month treatment with a diet devoid of the offending sugar demonstrated significant improvement in 56% of subjects. Vernia and colleagues69 studied 230 consecutive patients with IBS with no history of milk intolerance. Typical of a Mediterranean population, lactose intolerance was diagnosed by breath testing in 157 (68%) of 230 patients. Of the 110 patients who complied with the diet, symptoms "subsided" in 44%, were "reduced" in 39%, and were unchanged in 15%. Partial symptom improvement was reported in 20% of subjects who either were noncompliant with the diet or were lactose absorbers. There was no relationship between pretrial symptoms and dietary response, although the authors noted that the occurrence of symptoms during the breath test was predictive of a response to diet. In an uncontrolled prospective evaluation during a 5-year period, 14 of 16 lactose-intolerant patients with IBS reported marked improvement in symptoms.70 This was also associated with a 75% reduction in clinic visits. Only one study has evaluated the use of supplemental lactase in a double-blind, placebo-controlled trial.71 Twelve subjects were treated with lactase or placebo in a crossover trial. Eight of 12 subjects were lactase nonpersistent, ie, they had lost documented activity of the enzyme lactase. Lactase supplementation was not associated with symptom improvement regardless of lactase status.
PSYCHOLOGICAL THERAPIES
Psychological therapies can be broadly classified as psychotherapy, behavior therapy, hypnotherapy, and multicomponent therapy. For purposes of analysis, each category is reviewed separately.
Hypnotherapy
Three of 6 articles were excluded because they were uncontrolled.72-74 All 3 studies noted improvement with "gut-directed hypnotherapy" and reported response rates of 55%, 84%, and 93%.
Included studies also demonstrated benefits. Prior and colleagues75 reported improved tolerance to rectal balloon distention in diarrhea-predominant but not constipation-predominant IBS. No changes in rectal sensation were seen in a control group of 15 patients with IBS who did not receive hypnotherapy. Thirteen of 15 hypnotherapy-treated patients considered themselves improved. Whorwell et al,76 in their initial published trial of gut-directed hypnotherapy, reported hypnotherapy superior to placebo. Thirty subjects were randomized after a 2-week washout period. As placebo, a physician without specific training provided counseling focused on discussion of symptoms and exploration of emotional and stress factors contributing to symptoms. After a 3-month treatment period that included 7 therapy sessions, both groups showed significant improvement in scores for abdominal pain, distention, and well-being. No significant improvement was seen in the control group for bowel habit. Hypnotherapy was superior to control treatment in all measures. Galovski and Blanchard77 compared hypnotherapy with a symptom-monitoring wait-list condition in 6 matched pairs of patients with IBS. Hypnotherapy-treated patients had significant improvements in a composite score measuring symptoms of abdominal pain, diarrhea, constipation, bloating, flatulence, belching, and nausea. Individually, symptoms of pain, constipation, and flatulence showed significant improvement. No significant change was seen in depression scores, but significant improvement was seen in anxiety.
Psychotherapy
Four articles on cognitive therapy and psychotherapy were identified.78-81 All studies were randomized, controlled trials but were subject to bias. Svedlund et al80 randomized 101 of 119 recruited outpatients to medical therapy alone or medical therapy plus dynamically oriented individual psychotherapy. At 3 and 15 months, both groups demonstrated improvement in somatic and mental symptoms. Psychotherapy significantly improved total somatic symptom score and abdominal pain at 3 and 15 months and bowel dysfunction at 15 months. Psychopathological symptoms improved similarly between groups.
Psychotherapy was found to be superior to supportive listening in a randomized trial of 102 consecutively recruited patients.78 The psychotherapy group received 7 treatment sessions during 3 months, while the supportive listening group received 5 sessions during the same period. After 3 months, the psychotherapy group had fewer abdominal symptoms and better quality of life. Psychological symptom scores improved for women but not men.
Greene and Blanchard79 randomized 20 patients to individualized cognitive therapy or daily symptom monitoring. Treatment consisted of two 1-hour sessions weekly for 2 weeks followed by weekly sessions for the next 6 weeks. Improvement was measured by means of a composite primary symptom reduction (CPSR) score based on symptoms of pain, tenderness, diarrhea, and constipation. Clinically significant improvement was defined as a decrease in the CPSR of 50% or more.82 Eight of 10 patients receiving cognitive therapy showed clinically significant improvement compared with 1 of 10 in the symptom monitoring group. Sustained improvement was seen at 3-month follow-up.
Cognitive therapy has also been compared with self-help support groups or symptom monitoring in a group of 34 patients with IBS.81 Individual cognitive therapy was provided in two 1-hour sessions weekly for the first 2 weeks followed by weekly sessions for the next 6 weeks. Self-help support groups met weekly for 8 weeks. During self-help group sessions, educational information regarding IBS was provided and subjects shared experiences regarding their symptoms. Using a 50% or greater reduction in CPSR score as a criterion for clinically significant improvement, improvement occurred in 10 of 12 patients in the cognitive therapy group, 2 of 12 patients in the self-help group, and 1 of 10 patients in the symptom monitoring group. The cognitive therapy group also showed significant improvements on psychological measures of anxiety and depression compared with the other groups. Improvements were maintained at a 3-month follow-up assessment.
Behavior Therapy
Five studies evaluating behavioral therapy met inclusion criteria83-87 and 3 compared behavioral with medical therapy.83-85 Medical therapy consisted of peppermint oil84; a combination of antidepressant-anxiolytic medication, antispasmodic agent, and fiber83; and "conventional" therapy at the discretion of the gastroenterologist.85 Stress management consisted of weekly interventions for between 4 and 15 weeks. Stress management was superior to peppermint oil in reducing frequency and severity of attacks.84 In addition, stress-managed patients reported greater confidence regarding their illness. Compliance was only 50% with peppermint oil, however, and a greater percentage of behaviorally-treated patients reported association of symptoms with stress. Corney et al85 reported that bowel retraining and pain management significantly reduced food avoidance and domestic avoidance and decreased symptoms of headache, irritability, stomach pain, and constipation. Diarrhea was not improved. Somatic distress, depression, and anxiety also improved over time. Finally, Bennett and Wilkinson83 demonstrated that a progressive muscle relaxation technique better reduced anxiety than did medical therapy. Digestive symptoms improved similarly in both groups. The duration of this study was only 8 weeks, and 9 of 33 subjects dropped out.
Two studies evaluated relaxation therapy using symptom assessment as a control. Blanchard and colleagues86 reported that 4 of 8 patients treated with relaxation therapy experienced 50% or greater reduction in CPSR score compared with 1 of 8 control subjects. Relaxation therapy was conducted with 2 sessions during the first week followed by weekly sessions for the next 6 weeks. This was a short-duration trial with posttreatment symptoms assessed 4 weeks after completion of therapy. Lynch and Zamble87 reported that eight 2-hour sessions of relaxation therapy led to significant reductions in CPSR scores in 7 of 11 subjects compared with none of 10 control subjects. These gains were maintained at 5 months after the treatment phase ended.
Multicomponent Treatment
Multicomponent therapy incorporates elements of education, relaxation therapy, biofeedback, and cognitive therapy or psychotherapy. Seven studies met inclusion criteria.88-94 Most of the work in this area comes from Blanchard and colleagues. Neff and Blanchard94 published their initial experience in 1987. They developed an 8-week program consisting of progressive relaxation, thermal biofeedback, education, and stress management. After encouraging results in their initial 4 subjects, 10 patients treated with multicomponent therapy were compared with 9 control subjects. Six of 10 treated patients had 50% or greater reduction in CPSR score compared with 1 of 9 control subjects. Control subjects were subsequently offered therapy, and all subjects were followed up for several years. Reductions in CPSR score of 50% or greater were seen in 8 of 17 patients at 1 year and 8 of 14 patients at 2 years.90, 93
Blanchard et al95 also compared multicomponent therapy with attention placebo and symptom monitoring. The attention placebo group received contact time equivalent to that of the multicomponent therapy group; however, the exposure involved general counseling such as dietary measures and nonspecific support. Initially, 30 patients seeking nondrug therapy for IBS were studied. Two weeks after therapy was completed, CPSR score reductions of 50% or more were seen in 6 of 10 patients treated with multicomponent therapy and 5 of 10 patients treated with attention placebo. Two of 10 patients in the symptom-monitoring group improved. The authors then increased sample sizes in each group and followed the same protocol with the exception that follow-up was performed 4 weeks after completing interventions. Reductions in CPSR score of 50% or greater were seen in 16 of 31 subjects in the multicomponent therapy group, 14 of 30 patients treated with attention placebo, and 10 of 31 control subjects. Differences between groups were not significant.
Guthrie et al89 compared psychotherapy, relaxation, and medical therapy with medical therapy alone. One hundred two of 115 consecutively recruited patients with medically refractory IBS were assessed at baseline and 3 and 12 months. After 3 months, treated patients had significantly less pain, distention, and diarrhea, but not constipation. Assessments by blinded gastroenterologists confirmed improvements in pain and diarrhea. Follow-up interviews at 1 year showed that 28 of 31 patients initially considered improved had sustained improvement. In the control group, 4 of 10 patients with spontaneous improvement remained improved at 1 year. Thirty control subjects were subsequently treated with multicomponent therapy and 21 of 30 improved.
A multicomponent model using education, relaxation therapy, and cognitive therapy along with medical therapy was compared with medical therapy alone in consecutively recruited patients with IBS.88 Twenty-four of 26 randomized patients completed the study. Multicomponent behavioral therapy led to significant reductions in overall symptom scores as well as improved well-being, quality of life, and perceptions of control of health. Rectovisceral perception assessed by balloon distention was unchanged.
Meta-analysis of Psychological Therapies
Included studies evaluating psychological therapies are summarized in Table 2. Overall, these studies are highly subject to bias. None was well blinded, and only 2 studies reported the assessor to be blinded as well.78, 89 While responses to psychological interventions appear robust, the control group was typically symptom monitoring alone. In that regard, there is no true placebo group and it is difficult to estimate the true net therapeutic gain. It is possible to evaluate studies that included a true placebo group.81, 84, 95 Payne and Blanchard81 compared cognitive therapy with support groups, while Blanchard and colleagues95 compared a multicomponent behavioral therapy with an attention placebo control. Shaw et al84 compared stress management with a peppermint oil–treated group. Several other studies used appropriate control groups, but results were not reported in a way that allowed inclusion in the meta-analysis.76, 78, 80, 83, 85, 88-89 Results of the meta-analysis are shown in Figure 2. Psychological therapy was modestly favored over other interventions. Comparisons made with a fixed-effects model returned an odds ratio (95% confidence interval) of 2.38 (1.19-4.68). There was not significant heterogeneity among studies (2 = 5.90; P = .12).
|
|
|
|
Table 2. Overview of Included Trials of Psychological Therapies in Irritable Bowel Syndrome
|
|
|
|
|
|
|
Figure 2. Meta-analysis of psychological therapies compared with interventions other than symptom monitoring. OR indicates odds ratio; CI, confidence interval.
|
|
|
COMMENT
The difficulties encountered in treating IBS often lead physicians and patients to seek unconventional therapies. This review explored treatment options beyond the scope of commonly used therapies. For many therapies, no published medical literature could be found. For reviewable therapies, available literature varied greatly in both depth and quality.
No therapy could be considered well supported by existing literature, but the Chinese herbal medicine and psychological therapy currently offer the best evidence. The single trial of Chinese medicine is quite rigorous but obviously requires replication.15 This study raises interesting questions. Is there a subset of patients with IBS who are more likely to benefit from Chinese herbal medicine? Are there symptoms or psychological traits that predict response? It is equally important to understand why herbal therapy appears efficacious. Given the scarcity of effective pharmacologic agents to treat IBS, the potential for drug development would be significant.
While Chinese medicine offers only one study of high quality, psychological therapies offer many studies of lesser quality. These studies are highly prone to selection bias, as enrolled patients generally view this therapy favorably. Many of the studies are further degraded by the absence of a true control group. Given the generous placebo response that accompanies trials of functional bowel disorders, symptom monitoring alone is an inadequate control. Trials with reasonable control groups report more modest benefits76, 78, 80, 83, 88 or show no benefit at all.85, 95 These trials are further hampered by the absence of clear blinding on the part of the assessor. Only 2 of the included trials of psychological therapy reported that the assessor was blinded.78, 89 Although the coexistence of psychopathology in IBS is well established, and psychotherapy would intuitively seem effective, better studies are needed.
Dietary factors play an important role in symptom generation for many patients with IBS. True food allergy is extremely uncommon, while food intolerance is quite common. Elimination of offending foodstuffs is reasonable if a clear trigger is seen, but elimination diets are difficult and may have adverse nutritional consequences. Elimination diets and oral cromolyn appear equally efficacious in the treatment of unexplained chronic diarrheal illness, which would make cromolyn a reasonable choice before elimination diets are initiated.54-57
Carbohydrate intolerance in IBS is probably much more common than carbohydrate malabsorption. Lactose and fructose intolerance may not be more prevalent in IBS than in the baseline population, but patients with IBS develop greater symptoms as a result of exposure.62-64 Elimination of offending dietary substances appears beneficial, but use of lactase has not been shown to be effective.71 At present, it would seem that breath testing might not confer diagnostic advantages over a careful dietary history.
The role of gut flora in IBS is being actively investigated. Attention has recently been focused on bacterial overgrowth and postenteritic IBS, but both areas require further clarification. Small-intestinal bacterial overgrowth should be considered in patients with compatible symptoms and a predisposition to that disorder (diabetic, scleroderma, postsurgical anatomy, etc). The role of bacterial overgrowth in IBS awaits the results of well-designed prospective trials. Studies of postinfectious IBS are needed that address whether symptom origination is physiological or psychological. Although alteration of intestinal flora is an appealing and potentially therapeutically rewarding area of investigation, current studies do not support the routine use of probiotics in patients with IBS and large, placebo-controlled, double-blind trials need to be performed.
Finally, the efficacy of digestive aids such as peppermint oil remains to be seen. While a modest benefit is suggested by meta-anlysis of available controlled trials evaluating peppermint oil, the brief duration of therapy in these trials mandates caution when the results are interpreted. Ginger has been studied primarily in the setting of postoperative nausea and vomiting. Its use in IBS is unstudied. The use of digestive enzymes beyond lactase has not been carefully evaluated and cannot be recommended.
In conclusion, a wide variety of alternative therapies are presently used in the management of IBS. Although there are likely to be alternative therapies that are efficacious in the management of this condition, none has made a strong case based on existing medical evidence to date. Additional studies need to be performed in this area with careful attention to trial design and outcome measures.
AUTHOR INFORMATION
Corresponding author and reprints: Michael P. Jones, MD, Department of Internal Medicine, Northwestern Memorial Hospital, 251 E Huron, Galter 4-104, Chicago, IL 60611 (e-mail: mpjones{at}nmh.org).
Accepted for publication June 13, 2002.
From the Division of Gastroenterology and Hepatology, Department of Internal Medicine, Northwestern University Medical School, Chicago, Ill.
REFERENCES
| |
1. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112:2120-2137.
FULL TEXT
|
ISI
| PUBMED
2. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology. 1987;92(5, pt 1):1282-1284.
3. Switz DM. What the gastroenterologist does all day: a survey of a state society's practice. Gastroenterology. 1976;70:1048-1050.
ISI
| PUBMED
4. Whitehead WE, Burnett CK, Cook III EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248-2253.
FULL TEXT
|
ISI
| PUBMED
5. Talley NJ, Zinsmeister AR, Melton III LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995;142:76-83.
FREE FULL TEXT
6. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736-1741.
FULL TEXT
|
ISI
| PUBMED
7. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-1580.
FULL TEXT
|
ISI
| PUBMED
8. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 1988;95:232-241.
ISI
| PUBMED
9. Glaxo Wellcome Decides to Withdraw Lotronex From the Market. FDA Talk Paper, November 28, 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01058.html. Accessed November 21, 2002.
10. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 2001;96:1698-1703.
FULL TEXT
|
ISI
| PUBMED
11. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135:262-268.
FREE FULL TEXT
12. Giese LA. A study of alternative health care use for gastrointestinal disorders. Gastroenterol Nurs. 2000;23:19-27.
FULL TEXT
| PUBMED
13. Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut. 1986;27:826-828.
FREE FULL TEXT
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
FULL TEXT
|
ISI
| PUBMED
15. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA. 1998;280:1585-1589.
FREE FULL TEXT
16. Yadav SK, Jain AK, Tripathi SN, Gupta JP. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res. 1989;90:496-503.
PUBMED
17. Langmead L, Rampton DS. Herbal treatment in gastrointestinal and liver disease—benefits and dangers. Aliment Pharmacol Ther. 2001;15:1239-1252.
FULL TEXT
|
ISI
| PUBMED
18. Arfeen Z, Owen H, Plummer JL, Ilsley AH, Sorby-Adams RA, Doecke CJ. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intensive Care. 1995;23:449-452.
ISI
| PUBMED
19. Visalyaputra S, Petchpaisit N, Somcharoen K, Choavaratana R. The efficacy of ginger root in the prevention of postoperative nausea and vomiting after outpatient gynaecological laparoscopy. Anaesthesia. 1998;53:506-510.
FULL TEXT
|
ISI
| PUBMED
20. Phillips S, Ruggier R, Hutchinson SE. Zingiber officinale (ginger)—an antiemetic for day case surgery. Anaesthesia. 1993;48:715-717.
ISI
| PUBMED
21. Bone ME, Wilkinson DJ, Young JR, McNeil J, Charlton S. Ginger root—a new antiemetic: the effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia. 1990;45:669-671.
ISI
| PUBMED
22. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84:367-371.
FREE FULL TEXT
23. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1991;38:19-24.
FULL TEXT
|
ISI
| PUBMED
24. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness: a controlled trial on the open sea. Acta Otolaryngol. 1988;105:45-49.
PUBMED
25. Odes HS, Madar Z. A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Digestion. 1991;49(2):65-71.
26. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101:55-65.
ISI
| PUBMED
27. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32:765-768.
ISI
| PUBMED
28. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138:125-128.
FULL TEXT
|
ISI
| PUBMED
29. Carling I, Svedberg LE, Hulten S. Short term treatment of the irritable bowel syndrome: a placebo-controlled trial of peppermint oil against hyoscyamine. Opusc Med. 1989;34:55-57.
30. Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicentre trial. Br J Clin Pract. 1984;38:394, 398.
ISI
| PUBMED
31. Nash P, Gould SR, Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract. 1986;40:292-293.
ISI
| PUBMED
32. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. BMJ. 1979;2:835-836.
33. Lawson MJ, Knight RE, Tran K, Walker G, Roberts-Thompson IC. Failure of enteric-coated peppermint oil in the irritable bowel syndrome: a randomized, double-blind crossover study. J Gastroenterol Hepatol. 1988;3:235-238.
34. Talley NJ, Phillips SF, Melton LJ, Mulvihill C, Wiltgen C, Zinsmeister AR. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut. 1990;31:77-81.
FREE FULL TEXT
35. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93:1131-1135.
FULL TEXT
|
ISI
| PUBMED
36. McKendrick MW. Post Salmonella irritable bowel syndrome—5 year review. J Infect. 1996;32:170-171.
37. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314:779-782.
FREE FULL TEXT
38. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. 1999;318:565-566.
FREE FULL TEXT
39. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-811.
FREE FULL TEXT
40. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150-153.
FULL TEXT
|
ISI
| PUBMED
41. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400-406.
FREE FULL TEXT
42. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506.
FULL TEXT
|
ISI
| PUBMED
43. Riordan SM, McIver CJ, Duncombe VM, Thomas MC, Nagree A, Bolin TD. Small intestinal bacterial overgrowth and the irritable bowel syndrome. Am J Gastroenterol. 2001;96:2506-2508.
FULL TEXT
|
ISI
| PUBMED
44. Mishkin D, Mishkin S. Re: Pimentel et al—Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2001;96:2505-2506.
ISI
| PUBMED
45. Jones MP, Craig R, Olinger E. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome: the cart lands squarely in front of the horse. Am J Gastroenterol. 2001;96:3204-3205.
PUBMED
46. Cuoco L, Cammarota G, Jorizzo R, Gasbarrini G. Small intestinal bacterial overgrowth and symptoms of irritable bowel syndrome. Am J Gastroenterol. 2001;96:2281-2282.
FULL TEXT
|
ISI
| PUBMED
47. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231-1238.
FULL TEXT
|
ISI
| PUBMED
48. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: a randomised double-blind placebo-controlled crossover study. Dig Liver Dis. 2000;32:294-301.
FULL TEXT
|
ISI
| PUBMED
49. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108:975-982.
FULL TEXT
|
ISI
| PUBMED
50. Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr. 1999;129(7, suppl):1451S-1453S.
51. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol. 1998;93:2184-2190.
FULL TEXT
|
ISI
| PUBMED
52. Bentley SJ, Pearson DJ, Rix KJ. Food hypersensitivity in irritable bowel syndrome. Lancet. 1983;2:295-297.
ISI
| PUBMED
53. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187-1189.
FULL TEXT
|
ISI
| PUBMED
54. Lunardi C, Bambara LM, Biasi D, et al. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy. 1991;21:569-572.
FULL TEXT
|
ISI
| PUBMED
55. Bolin TD. Use of oral sodium cromoglycate in persistent diarrhoea. Gut. 1980;21:848-850.
FREE FULL TEXT
56. Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type: multicenter study of 428 patients. Scand J Gastroenterol. 1995;30:535-541.
ISI
| PUBMED
57. Stefanini GF, Prati E, Albini MC, et al. Oral disodium cromoglycate treatment of irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol. 1992;87:55-57.
ISI
| PUBMED
58. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-147.
FREE FULL TEXT
59. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48:272-282.
FREE FULL TEXT
60. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci. 1999;44:1317-1321.
FULL TEXT
|
ISI
| PUBMED
61. Bianchi Porro G, Parente F, Sangaletti O. Lactose intolerance in adults with chronic unspecific abdominal complaints. Hepatogastroenterology. 1983;30:254-257.
PUBMED
62. Newcomer AD, McGill DB. Irritable bowel syndrome: role of lactase deficiency. Mayo Clin Proc. 1983;58:339-341.
ISI
| PUBMED
63. Ferguson A, MacDonald DM, Brydon WG. Prevalence of lactase deficiency in British adults. Gut. 1984;25:163-167.
FREE FULL TEXT
64. Vesa TH, Seppo LM, Marteau PR, Sahi T, Korpela R. Role of irritable bowel syndrome in subjective lactose intolerance. Am J Clin Nutr. 1998;67:710-715.
ABSTRACT
65. Rumessen JJ, Gudmand-Hoyer E. Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol, and fructose-sorbitol mixtures. Gastroenterology. 1988;95:694-700.
ISI
| PUBMED
66. Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology. 1990;99:1016-1020.
ISI
| PUBMED
67. Fernandez-Banares F, Esteve-Pardo M, de Leon R, et al. Sugar malabsorption in functional bowel disease: clinical implications. Am J Gastroenterol. 1993;88:2044-2050.
ISI
| PUBMED
68. Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J. 2000;2:583-587.
ISI
| PUBMED
69. Vernia P, Ricciardi MR, Frandina C, Bilotta T, Frieri G. Lactose malabsorption and irritable bowel syndrome: effect of a long-term lactose-free diet. Ital J Gastroenterol. 1995;27:117-121.
ISI
| PUBMED
70. Bohmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. Eur J Gastroenterol Hepatol. 2001;13:941-944.
FULL TEXT
|
ISI
| PUBMED
71. Lisker R, Solomons NW, Perez Briceno R, Ramirez Mata M. Lactase and placebo in the management of the irritable bowel syndrome: a double-blind, cross-over study. Am J Gastroenterol. 1989;84:756-762.
ISI
| PUBMED
72. Harvey RF, Hinton RA, Gunary RM, Barry RE. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. Lancet. 1989;1:424-425.
FULL TEXT
|
ISI
| PUBMED
73. Vidakovic-Vukic M. Hypnotherapy in the treatment of irritable bowel syndrome: methods and results in Amsterdam. Scand J Gastroenterol Suppl. 1999;230:49-51.
FULL TEXT
| PUBMED
74. Whorwell PJ, Prior A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome: further experience. Gut. 1987;28:423-425.
FREE FULL TEXT
75. Prior A, Colgan SM, Whorwell PJ. Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut. 1990;31:896-898.
FREE FULL TEXT
76. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet. 1984;2:1232-1234.
ISI
| PUBMED
77. Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback. 1998;23:219-232.
FULL TEXT
|
ISI
| PUBMED
78. Guthrie E, Creed F, Dawson D, Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry. 1993;163:315-321.
FREE FULL TEXT
79. Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol. 1994;62:576-582.
FULL TEXT
|
ISI
| PUBMED
80. Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet. 1983;2:589-592.
ISI
| PUBMED
81. Payne A, Blanchard EB. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol. 1995;63:779-786.
FULL TEXT
|
ISI
| PUBMED
82. Blanchard EB, Schwarz SP. Adaptation of a multicomponent treatment for irritable bowel syndrome to a small-group format. Biofeedback Self Regul. 1987;12:63-69.
FULL TEXT
|
ISI
| PUBMED
83. Bennett P, Wilkinson S. A comparison of psychological and medical treatment of the irritable bowel syndrome. Br J Clin Psychol. 1985;24(pt 3):215-216.
84. Shaw G, Srivastava ED, Sadlier M, Swann P, James JY, Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion. 1991;50:36-42.
FULL TEXT
|
ISI
| PUBMED
85. Corney RH, Stanton R, Newell R, Clare A, Fairclough P. Behavioural psychotherapy in the treatment of irritable bowel syndrome. J Psychosom Res. 1991;35:461-469.
FULL TEXT
|
ISI
| PUBMED
86. Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul. 1993;18:125-132.
FULL TEXT
|
ISI
| PUBMED
87. Lynch PM, Zamble E. A controlled behavioral study of irritable bowel syndrome. Behav Ther. 1989;20:509-523.
FULL TEXT
88. Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol. 2000;95:981-994.
ISI
| PUBMED
89. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology. 1991;100:450-457.
ISI
| PUBMED
90. Schwarz SP, Blanchard EB, Neff DF. Behavioral treatment of irritable bowel syndrome: a 1-year follow-up study. Biofeedback Self Regul. 1986;11:189-198.
FULL TEXT
|
ISI
| PUBMED
91. Schwarz SP, Taylor AE, Scharff L, Blanchard EB. Behaviorally treated irritable bowel syndrome patients: a four-year follow-up. Behav Res Ther. 1990;28:331-335.
FULL TEXT
|
ISI
| PUBMED
92. Blanchard EB, Schwarz SP, Neff DF, Gerardi MA. Prediction of outcome from the self-regulatory treatment of irritable bowel syndrome. Behav Res Ther. 1988;26:187-190.
FULL TEXT
|
ISI
| PUBMED
93. Blanchard EB, Schwarz SP, Neff DF. Two-year follow-up of behavioral treatment of irritable bowel syndrome. Behav Ther. 1988;19:67-73.
FULL TEXT
94. Neff DF, Blanchard EB. A multi-component treatment for irritable bowel syndrome. Behav Ther. 1987;18:70-83.
FULL TEXT
95. Blanchard EB, Schwarz SP, Suls JM, et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther. 1992;30:175-189.
FULL TEXT
|
ISI
| PUBMED
96. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in US women. Am J Gastroenterol. 2002;97:2803-2811.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Complementary and alternative medicine for treatment of irritable bowel syndrome
Shen and Nahas
cfp 2009;55:143-148.
ABSTRACT
| FULL TEXT
Behavioral and Complementary Approaches for the Treatment of Irritable Bowel Syndrome
Wald and Rakel
Nutr Clin Pract 2008;23:284-292.
ABSTRACT
| FULL TEXT
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller et al.
Gut 2007;56:1770-1798.
ABSTRACT
| FULL TEXT
Functional Gastrointestinal Disorders: An Update for the Psychiatrist
Jones et al.
Psychosomatics 2007;48:93-102.
ABSTRACT
| FULL TEXT
Acupuncture treatment in irritable bowel syndrome
Schneider et al.
Gut 2006;55:649-654.
ABSTRACT
| FULL TEXT
Hypnosis in Contemporary Medicine
Stewart
Mayo Clin Proc. 2005;80:511-524.
ABSTRACT
Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome
Cremonini and Talley
Evid. Based Med. 2003;8:160-160.
FULL TEXT
OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03)
Evid. Based Nurs. 2003;6:e1-12.
FULL TEXT
Review of Alternative Therapies for IBS
JWatch Gastroenterology 2003;2003:3-3.
FULL TEXT
|
